Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of MDI-1228 Ophthalmic Solution in Healthy Volunteers
NCT05969236Phase 1Completed
- Start
- Oct 2023
- Primary completion
- Apr 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of MDI-1228 in allergic conjunctivitis (AC) (4 arms). Primary endpoints: Treatment Emergent Adverse Events, Respiratory Rate and 17 more. Started Oct 2023; status: completed.
02
Drugs
MDI-1228
03
Conditions
allergic conjunctivitis (AC)
Beyond the preview
Go deeper on NCT05969236.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05969236.